Toronto Stock Exchange Symbol: MS
EDMONTON, April 20 /CNW/ - BioMS Medical Corp (TSX: MS), a leading
developer in the treatment of multiple sclerosis (MS), is pleased to announce
Dr. Clyde E. Markowitz as the lead investigator in the United States for the
Company's pivotal phase III clinical trial of its lead drug, MBP8298, for the
treatment of secondary progressive multiple sclerosis.
Dr. Markowitz is Director of the Multiple Sclerosis Center at the
Hospital of the University of Pennsylvania in Philadelphia. He is an Assistant
Professor of Neurology at the University of Pennsylvania School of Medicine
and an attending neurologist at the Hospital of the University of
"With few approved therapies for secondary progressive MS, this trial is
important for the MS community and patients," said Dr. Markowitz. "I am
pleased to play a key role in assessing the impact that MBP8298 may have on
delaying disease progression of secondary progressive MS."
Dr. Markowitz is a member of the American Academy of Neurology and the
International MS Forum. Dr. Markowitz is also Chairman of the clinical
advisory committee for the Delaware Valley chapter of the National Multiple
Sclerosis Society and a member of the Penn Neuro Care, MS section of the
National Multiple Sclerosis Society. Dr. Markowitz is the author and co-author
of a number of publications in the field of MS, and he serves as an ad hoc
reviewer for Multiple Sclerosis, Journal of Clinical Immunology,
Neuro-Rehabilitation and Neural Repair, and The Consultant.
BioMS Medical recently received clearance from the United States Food and
Drug Administration (FDA) for the initiation of a pivotal phase III clinical
trial to investigate the use of MBP8298 as a treatment for patients with
secondary progressive MS.
The pivotal phase III clinical trial in the US, named MAESTRO-03, will be
a randomized, double-blind study enrolling approximately 510 patients who will
be administered either MBP8298 or placebo intravenously every six months for a
period of two years. The primary clinical endpoint for the trial is defined as
a statistically and clinically significant increase in the time to progression
of the disease as measured by the Expanded Disability Status Scale (EDSS), in
patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all
MS patients are HLA-DR2 and/or HLA-DR4 positive).
About BioMS Medical Corp.
BioMS Medical is a biotechnology company engaged in the development and
commercialization of novel therapeutic technologies. BioMS Medical's lead
technology, MBP8298, is for the treatment of multiple sclerosis and is being
evaluated in two pivotal phase III clinical trials for secondary progressive
MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United
States. It additionally is being evaluated for relapsing remitting MS patients
in a Phase II trial in Europe entitled MINDSET-01. For further information
please visit our website at www.biomsmedical.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of BioMS Medical with respect to
its performance, business and future events. Such statements are subject to a
number of risks, uncertainties and assumptions. Actual results and events may
For further information:
For further information: Tony Hesby, Ryan Giese, Corporate
Communications, BioMS Medical Corp., (780) 413-7152, (780) 408-3040 Fax,
E-mail: email@example.com, Internet: www.biomsmedical.com; James Smith,
Investor Relations, (416) 815-0700 ext. 229, (416) 815-0080 Fax, E-mail:
firstname.lastname@example.org; Mr. Barry Mire, Investor Relations, Phone: (514)
939-3989, E-mail: email@example.com